The FDA approved atezolizumab plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase III ATOMIC trial, cutting the risk of recurrence or death by about 50%. The decision adds another checkpoint-based option for a biomarker-defined subgroup where risk remains high after surgery.